NeuroSense Therapeutics Ltd. NRSN
1.69 USD -0.07 (-3.98%)
Regular-session close
1.71 +0.02 +1.18%
After hours · Nov 13, 4:00 PM ET
1.60 Day range 1.78
1.10 52-week range 25.40
- YTD
- -89.01%
- 1 year
- -90.80%
News
benzinga.com NeuroSense Adds New Data To PrimeC Application, Delays Health Canada Filing To March 2027 Expanded package to include new neurofilament light chain (NfL) analysis; Health Canada confirms March 2027 filing timelineSubmission would be PrimeC's first marketing application in any…
benzinga.com HC Wainwright & Co. Downgrades NeuroSense Therapeutics to Neutral HC Wainwright & Co. analyst Lander Egaña Gorroño downgrades NeuroSense Therapeutics (NASDAQ:NRSN) from Buy to Neutral.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…benzinga.com NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million. Circle8 Group…benzinga.com NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027 NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative…
benzinga.com SpaceX, Qualcomm and 3 Stocks to Watch Heading Into Monday Stocks in focus: SpaceX jumps after 3 launches; CL Workshop plans $200M ATM; Qualcomm files share offering; Pasqal names IR chief; Neurosense warned.benzinga.com NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative…
benzinga.com HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52 HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.
benzinga.com NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(2.10). This is a 43.24 percent increase over losses of $(3.70) per share from the same period last year.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)…
benzinga.com This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated coverage with Buy ratings on SpaceX, Securitize ; Overweight on Londian Wason.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies…
benzinga.com This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).benzinga.com HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8 HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $8.
benzinga.com NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares…
benzinga.com Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include…benzinga.com NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's…
benzinga.com NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Sclerosis Has Met Its Primary Efficacy Endpoint First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALSTDP-43 pathology is present in more than 97% of ALS cases and…
benzinga.com NeuroSense Therapeutics Announces Data From Its Phase 2 RoAD Trial Of PrimeC In Alzheimer's Disease Demonstrates Multiple Protein Biomarker Changes; Distinctive Changes Also Seen In Levels Of Other Major Neurodegenerative Disease Misfolding Proteins NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session benzinga.com NeuroSense Therapeutics Secures Japanese Patent 7857044 Covering Its Lead Drug Candidate For Treatment Of Amyotrophic Lateral Sclerosis Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session benzinga.com NeuroSense Therapeutics Granted Patent From Brazilian Patent And Trademark Office Entitled 'Compositions Comprising Ciprofloxacin And Celecoxib' NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today…
benzinga.com Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026 Notifications have no immediate effect on the listing or trading of the Company's securities on NasdaqNasdaq has provided the Company until September 29, 2026 to regain compliance with both…
benzinga.com NeuroSense Therapeutics FY EPS $(0.44) Misses $(0.35) Estimate NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.35) by 25.71 percent.
benzinga.com This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $175 price target and CROX has a Neutral rating.benzinga.com Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3 Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session benzinga.com NeuroSense Therapeutics Announces Availability Of Additional Long-Term Survival Data From PARADIGM Phase 2b Clinical Trial Evaluating PrimeC In Patients With ALS NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today…
benzinga.com NeuroSense Therapeutics Granted Australia Patent For Its PrimeC NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the…
benzinga.com NeuroSense Therapeutics Granted Parent From U.S. Patent And Trademark Office For Use Of PrimeC Combination In Alzheimer' Disease NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the…
benzinga.com D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
benzinga.com NeuroSense Therapeutics' Analysis From Phase 2 NST-AD-001 Trial Of PrimeC Combination In Alzheimer's Demonstrates Favorable Tolerability For PrimeC NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion of…
benzinga.com NeuroSense Therapeutics Locks Database For Phase 2 RoAD Study Of PrimeC In Alzheimer's; Topline Results Expected Q1 2026 NeuroSense Therapeutics Ltd. ("NeuroSense") today announced that the database has been locked for its proof-of-concept, Phase 2 clinical trial of PrimeC in Alzheimer's disease (AD), known as the RoAD…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session benzinga.com NeuroSense Therapeutics Resumes Regulatory Push in Canada for ALS Drug PrimeC After Productive Talks NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that…
benzinga.com D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
benzinga.com FDA Completes Review Of IND Amendment Application And Authorizes NeuroSense To Initiate Pivotal Phase 3 Clinical Trial For Evaluation Of PrimeC, For ALS Treatment NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S.…
benzinga.com Neurosense Therapeutics Announces Phase 2b PARADIGM Study Results For PrimeC Showing Statistically Significant Reductions In Multiple Micrornas Linked To Alzheimer's Disease NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced new positive…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com NeuroSense Reports Phase 2 RoAD Trial Results, Says PrimeC Boosts Brain Connectivity In Alzheimer's, Shows Favorable Safety Profile Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profileCAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense…
benzinga.com NeuroSense Reports Statistically Significant Survival Benefit In ALS Phase 2b PARADIGM Study; 50% Of PrimeC Patients Remain Alive NeuroSense Therapeutics Ltd. (the "Company") Reports Additional Clinical Data from its Phase 2b PARADIGM Study More than three years from initiation of the Phase 2b PARADIGM Study, survival analyses…
benzinga.com NeuroSense Announces $500,000 Private Placement Of 333,334 Shares At $1.50/Share Financing at 40% premium to market price provides near-term bridge to anticipated milestonesCAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"),…
benzinga.com NeuroSense Reports Statistically Significant 18-Month Phase 2b Data Showing PrimeC Slows ALS Progression With Early Treatment Advantage NeuroSense Therapeutics Ltd. today announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in ALS. ●Statistically significant effect at 18 months (p=0.03) demonstrated by…
benzinga.com NeuroSense Therapeutics Says As Of August 20, 2025, ~20% Of People With ALS From The Company's Phase 2a Study, Including Those Continuing Under Compassionate Use, Remain On Primec For More Than 5.5 Years, Having Lived With Als For Over 7 Years; Across These Multi-Year Exposures, Treatment Remains Well Tolerated, With No New Safety Signals Observed To Date https://www.sec.gov/Archives/edgar/data/1875091/000121390025078783/ea0254016-6k_neurosense.htm
benzinga.com D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
benzinga.com D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
